Fennec Pedmarqsi® Gets Nod from UK NICE to Prevent Cisplatin-Induced Hearing Loss

 ~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~

~ Data from two open-label, randomized Phase 3 trials, SIOPEL 6 (pivotal) and the Clinical Oncology Group (COG) Protocol ACCL0431, demonstrated an approximate 50% reduction in the occurrence of cisplatin-induced ototoxicity in patients treated with cisplatin and sodium thiosulfate vs. those treated with cisplatin alone ~

~ There is a clear unmet need for the prevention of hearing loss caused by cisplatin and until now, there have been no preventative pharmacological interventions available, despite the significant lifelong impact hearing loss has on cancer patients ~

https://www.globenewswire.com/news-release/2024/12/20/3000452/0/en/Fennec-Pharmaceuticals-Announces-Pedmarqsi-Positive-Recommendation-by-NICE-for-the-Prevention-of-Cisplatin-Induced-Hearing-Loss-in-England-and-Wales.html